Isracann Biosciences Inc.
ISCNF
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -50.27% | -48.83% | -55.43% | -53.84% | -- |
| Depreciation & Amortization | -0.91% | 3.44% | 13.82% | 8.28% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -49.81% | -48.39% | -55.03% | -53.57% | -- |
| Operating Income | 49.81% | 48.39% | 55.03% | 53.57% | -- |
| Income Before Tax | 82.42% | 81.58% | -40.07% | -24.39% | -- |
| Income Tax Expenses | -- | -- | 151.12% | 151.12% | -- |
| Earnings from Continuing Operations | 82.44% | 81.60% | -40.75% | -24.92% | -- |
| Earnings from Discontinued Operations | -- | -- | 100.00% | 100.00% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 82.44% | 81.62% | -39.96% | -23.94% | -- |
| EBIT | 49.81% | 48.39% | 55.03% | 53.57% | -- |
| EBITDA | 50.27% | 48.83% | 55.43% | 53.84% | -- |
| EPS Basic | 83.19% | 82.26% | -27.78% | -11.00% | -- |
| Normalized Basic EPS | 54.22% | 50.00% | 54.36% | 59.95% | -- |
| EPS Diluted | 83.19% | 82.26% | -27.78% | -11.00% | -- |
| Normalized Diluted EPS | 54.22% | 50.00% | 54.36% | 59.95% | -- |
| Average Basic Shares Outstanding | 7.19% | 7.09% | 8.42% | 9.63% | -- |
| Average Diluted Shares Outstanding | 7.19% | 7.09% | 8.42% | 9.63% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |